Tom Brady has revealed that his dog, Junie, is a clone of his late pet, Lua, created through advanced biotech cloning technology from Colossal Biosciences. The seven-time Super Bowl champion and current FOX Sports broadcaster made the announcement in a statement from a company he has invested in, highlighting the use of non-invasive cloning technology through a simple blood draw of their elderly dog before she passed.
Colossal Biosciences, a biotech startup, announced the acquisition of animal cloning company Viagen Pets and Equine, marking its first major acquisition. While Brady’s cloned dog has received attention, Colossal also claims to have successfully cloned extinct dire wolves, a claim that has sparked debate among conservation groups. The International Union for Conservation of Nature and other organizations have questioned the validity of these claims, raising concerns about the intersection of biotechnology and conservation efforts.
Brady, who previously mentioned his late dog Lua, who died in December 2023, expressed his deep connection to his animals, stating that they mean the world to him and his family. The cloning of Junie has not only drawn media attention but has also brought visibility to the company’s broader goals of addressing extinction through genetic engineering.
As the debate over cloning and conservation continues, the announcement coincided with the NFL trade deadline, underscoring the unexpected intersection of sports and scientific innovation. While the biotech advancements have sparked both fascination and skepticism, they highlight the growing role of genetic technologies in shaping future conservation and personal legacy.
Colossal Biosciences’ website outlines its vision for reawakening the Earth’s lost wilds through genetic engineering and conservation efforts. The company’s claims, however, remain under scrutiny as the scientific community and conservationists continue to assess the validity and ethical implications of such technologies in the pursuit of ecological restoration.